Autoimmune Biologics Deal Benchmarks
Market Analysis
Autoimmune biologics remain one of the most actively licensed categories in biopharma, driven by large patient populations and proven commercial models. Phase 2 autoimmune biologic deals achieve a median total deal value of $3.0B, with upfront payments from $304M to $919M. The chronic treatment paradigm and multi-indication expansion potential create highly valuable licensing opportunities.
Milestone structures for autoimmune biologics balance development ($490M), regulatory ($858M), and commercial milestones ($1.1B). The 19/81 upfront/milestone structure reflects the de-risked Phase 2 stage and the established regulatory pathway for autoimmune indications.
Royalty rates range from 14% to 23.4% base, with escalation to 27.4% on blockbuster sales. Differentiation versus anti-TNF biologics, novel mechanisms (anti-TL1A, anti-IL-23, BCMA-targeting), and subcutaneous formulations drive premium royalty tiers. Multi-indication potential across RA, lupus, and IBD significantly enhances total deal economics.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the average deal value for autoimmune biologic licensing?
How does multi-indication potential affect autoimmune deal terms?
What autoimmune targets are commanding the highest deal premiums in 2026?
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating